KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations | DelveInsight

The KRAS inhibitors market is expected to experience strong growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline consisting of therapies such as Divarasib (RG6330; Roche/Chugai/Genentech), Olomorasib (LY3537982; Eli Lilly and Company), MK-1084 (Merck, Taiho, and Astex Pharmaceuticals), and others across the 7MM. G12C is the dominant KRAS mutation in NSCLC, making it a key focus of current therapies. Following the success of KRASG12C inhibitors, attention is shifting to KRASG12D as the next major target.

LAS VEGAS, Oct. 19, 2026 /PRNewswire/ -- DelveInsight's KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging KRAS inhibitor drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the KRAS Inhibitors Market Report

• The total KRAS inhibitors market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest KRAS inhibitors market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The report provides the total potential number of patients in the indications, such as Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, and others.
• The total incident cases of NSCLC were 539,400 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Leading KRAS inhibitor companies, such as Roche, Chugai, Genentech, Eli Lilly and Company, Merck, Taiho, Astex Pharmaceuticals, Cardiff Oncology, Genfleet Therapeutics, Innovent, Elicio Therapeutics, D3 Bio, Revolution Medicines, Astellas Pharma, BridgeBio Oncology Therapeutics, Arvinas, Quanta Therapeutics, and others, are developing novel KRAS inhibitor drugs that can be available in the KRAS inhibitors market in the coming years. 
• Some of the key KRAS inhibitor drugs in clinical trials include Divarasib (RG6330), Olomorasib (LY3537982), MK-1084, Onvansertib, DUPERT (fulzerasib/GFH925), ELI-002, D3S-001, Zoldonrasib (RMC-9805), Setidegrasib (ASP3082), BBO-11818, ARV-806, QTX3034, and others.

Discover the emerging landscape of KRAS inhibitors in cancer treatment @ https://www.delveinsight.com/report-store/kras-inhibitors-market

Key Factors Driving the KRAS Inhibitors Market 

• Rising Prevalence of KRAS-Mutated Cancers: KRAS mutations are frequently observed across major solid tumors, particularly colorectal, non-small cell lung, and pancreatic cancers. The substantial patient population with KRAS-driven tumors is increasing the need for targeted treatment options.
• Growing Adoption of KRAS-Targeted Therapies: The clinical availability of KRAS inhibitors has established a new targeted-treatment approach for patients with specific KRAS mutations. Increasing physician familiarity and treatment adoption are expected to support market expansion.
• Expansion Beyond KRAS G12C: Innovation is moving beyond KRAS G12C toward other clinically relevant mutations, including KRAS G12D and KRAS G12V. Development of inhibitors against these variants could significantly expand the addressable patient population.
• Increasing Investment in Oncology Drug Development: Pharmaceutical and biotechnology companies are increasing investment in precision oncology and KRAS-focused drug discovery. Strategic collaborations, licensing agreements, and acquisitions are further accelerating the development of next-generation KRAS inhibitors.
• Advances in Precision Medicine and Biomarker Testing: Greater use of molecular profiling and companion diagnostic testing is improving identification of patients with actionable KRAS mutations. Wider adoption of genomic testing is therefore supporting more targeted patient selection and treatment utilization.
• Expansion of Clinical Development Pipelines: A growing number of KRAS inhibitors including Divarasib (RG6330; Roche/Chugai/Genentech), Olomorasib (LY3537982; Eli Lilly and Company), MK-1084 (Merck, Taiho, and Astex Pharmaceuticals), Onvansertib (Cardiff Oncology), DUPERT (fulzerasib/GFH925; Genfleet Therapeutics and Innovent), ELI-002 (Elicio Therapeutics), D3S-001 (D3 Bio), and others are progressing through clinical development across multiple tumor types and mutation subtypes.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that combining KRAS-targeted therapies with other treatment modalities, such as immunotherapies or traditional chemotherapy, holds promise for improving treatment outcomes. The potential for combination therapies creates additional market opportunities and enhances the overall market strength of KRAS mutations.

KRAS Inhibitors Market Analysis

• A significant number of KRAS subtypes currently lack approved or effective treatment options, creating an opportunity for pan-KRAS therapies that could address a broader patient population across multiple KRAS mutations. 
• Onvansertib, for instance, has demonstrated pan-KRAS inhibitory activity in colorectal cancer, while companies such as ELICIO Therapeutics and Revolution Medicines are also advancing pan-KRAS-targeted approaches.
• Sotorasib has emerged as an important treatment option for KRAS G12C-mutated non-small cell lung cancer (NSCLC), representing a major advance in the treatment of a mutation historically considered difficult to target. 
• Continued clinical development and potential expansion into colorectal cancer and other KRAS G12C-driven malignancies could further broaden its application across solid tumors, reinforcing its role in precision oncology.
• Key pharmaceutical and biotechnology companies developing KRAS-targeted therapies include Roche and Genentech with divarasib (RG6330); Eli Lilly and Company with olomorasib (LY3537982); Merck, Taiho, and Astex Pharmaceuticals with calderasib (MK-1084); Cardiff Oncology with onvansertib; Genfleet Therapeutics and Innovent with fulzerasib (DUPERT); Elicio Therapeutics with ELI-002; and D3 Bio with elisrasib (D3S-001). 
• Several additional companies are also advancing KRAS-targeted candidates across various stages of clinical development.

Learn more about pan-KRAS inhibitor @ Global KRAS Inhibitors Market

KRAS Inhibitors Competitive Landscape

Some of the KRAS inhibitor drugs under development include Divarasib (RG6330; Roche/Chugai/Genentech), Olomorasib (LY3537982; Eli Lilly and Company), MK-1084 (Merck, Taiho, and Astex Pharmaceuticals), Onvansertib (Cardiff Oncology), DUPERT (fulzerasib/GFH925; Genfleet Therapeutics and Innovent), ELI-002 (Elicio Therapeutics), D3S-001 (D3 Bio), Zoldonrasib (RMC-9805; Revolution Medicines), Setidegrasib (ASP3082; Astellas Pharma), BBO-11818 (BridgeBio Oncology Therapeutics), ARV-806 (Arvinas), QTX3034 (Quanta Therapeutics), and others.

Eli Lilly's Olomorasib is an investigational, orally administered, potent, and highly selective second-generation KRAS G12C inhibitor. It is currently being evaluated in a first-line (1L) KRAS G12C-positive non-small cell lung cancer (NSCLC) clinical trial, alongside two other Phase III studies in NSCLC. In June 2025, the U.S. FDA granted Breakthrough Therapy Designation (BTD) to olomorasib for the treatment of certain patients with newly diagnosed metastatic KRAS G12C-mutant lung cancer and Orphan Drug Designation (ODD) for the treatment of KRAS G12C-mutant NSCLC.

Merck, Taiho, and Astex Pharmaceuticals' Calderasib is an investigational oral, selective KRAS G12C inhibitor being evaluated both as a monotherapy and in combination with pembrolizumab for the treatment of certain patients with colorectal cancer and NSCLC. Also known as MK-1084, calderasib is being developed through a collaboration and licensing agreement with Taiho Pharmaceutical and Astex Pharmaceuticals. The candidate is currently being evaluated in the Phase III KANDLELIT-012 and KANDLELIT-004 trials. In May 2026, the U.S. FDA granted BTD to calderasib for the first-line treatment of patients with advanced or metastatic NSCLC harboring KRAS G12C mutations and expressing PD-L1.

Roche/Chugai/Genentech's Divarasib (KRAS G12C, GDC-6036, RG6330) is an irreversible covalent inhibitor targeting the KRAS G12C mutant protein, thereby locking it into an inactive conformation. The candidate is currently being investigated across solid tumors, including first-line and second-line NSCLC.

The anticipated launch of these emerging therapies are poised to transform the KRAS inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the KRAS inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new KRAS inhibitors beyond sotorasib adagrasib, visit @ Approved KRAS Inhibitor Drugs

Recent Developments in the KRAS Inhibitors Market

• In August 2026, the US FDA granted Breakthrough Therapy Designation (BTD) to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation.
• In July 2026, Genentech announced positive results from the Phase III Krascendo 1 study evaluating divarasib against sotorasib or adagrasib in patients with previously treated KRAS G12C NSCLC. The study met its primary and key secondary endpoints, with divarasib achieving clinically meaningful and statistically significant improvements in both PFS and OS.
• In June 2026, Cardiff Oncology announced positive results from CRDF-004, a Phase II clinical trial evaluating onvansertib in combination with SoC regimens in patients with first-line RAS-mutated mcolorectal cancer. Results showed that onvansertib demonstrated deep and durable tumor shrinkage, including clinically meaningful improvements in ORR and PFS.
• In May 2026, Silexion Therapeutics announced positive preclinical findings from an ongoing translational immuno-oncology study evaluating SIL204 in human KRAS-mutated pancreatic cancer cells. Findings showed a statistically significant increase in surface expression of major histocompatibility complex class I (MHC-I), also known as HLA-ABC.
• In April 2026, Revolution Medicines announced positive topline results from its Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic PDAC who had been previously treated. It demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard-of-care cytotoxic chemotherapy delivered intravenously.
• In March 2026, Merck announced new data from the Phase I KANDLELIT-001 trial. Findings demonstrated that calderasib, both as monotherapy and in combination with pembrolizumab, provides durable antitumor activity and impressive survival rates. The ORR reached 72% in the combination group, and patients receiving the doublet therapy achieved a median PFS of 95%.
• In February 2026, Merck disclosed in its SEC filing that its Phase III drug candidate (calderasib) is covered under US patent protection, with exclusivity expected to extend until 2041.

KRAS Inhibitors Epidemiology Segmentation

The KRAS inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. KRAS mutations are seen most frequently in Colorectal Cancer, with LGSOC capturing the lowest patient share. The most frequent KRAS variant observed in NSCLC is G12C. In the US, KRASG12C is present in ~37% of NSCLC cases.

The KRAS inhibitor target patient pool is segmented into:

• Total Eligible Patient Pool for KRAS Inhibitors
• Total Cases of Selected Indications for KRAS Inhibitors
• Total Treated Cases in Selected Indications for KRAS Inhibitors

Scope of the KRAS Inhibitors Market Report

• KRAS Inhibitors Patient Population Forecast
• KRAS Inhibitors Therapeutics Market Size
• KRAS Inhibitors Pipeline Analysis
• KRAS Inhibitors Market Size and Trends
• KRAS Inhibitors Market Opportunity
• KRAS Inhibitors Market Unmet Needs
• KOL's Views on KRAS Inhibitors
• KRAS Inhibitors Market Access and Reimbursement

Discover KRAS inhibitor clinical trials 2026 @ KRAS Inhibitors Clinical Trials

Table of Contents

Related Reports

Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK and others.

Colorectal Cancer Market

Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CRC companies including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Exelixis, Agenus, Verastem Oncology, Adagene, Summit Therapeutics, AbbVie, Oncolytics Biotech, Sanofi, Revolution Medicines, Frontier Medicines, Jacobio Pharmaceuticals, and others.

Pancreatic Cancer Market

Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key pancreatic cancer companies including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, and others.

Ovarian Cancer Market

Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ovarian cancer companies, including pharmaand GmbH, GlaxoSmithKline (GSK), AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

View original content to download multimedia:https://www.prnewswire.com/news-releases/kras-inhibitors-market-is-set-for-expansion-during-the-forecast-period-20262036-supported-by-emerging-therapies-targeting-diverse-kras-mutations--delveinsight-302912208.html

SOURCE DelveInsight Business Research, LLP